Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells

References

• Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001; 2:133 - 40; http://dx.doi.org/10.1016/S1470-2045(00)00254-0; PMID: 11902563
   PubMed Web of Science ®Google Scholar
• Lacey JV Jr., Devesa SS, Brinton LA. Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen 2002; 39:82 - 8; http://dx.doi.org/10.1002/em.10062; PMID: 11921173
   PubMed Web of Science ®Google Scholar
• Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 2003; 21:28 - 34; http://dx.doi.org/10.1200/JCO.2003.03.088; PMID: 12506166
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007; 356:1670 - 4; http://dx.doi.org/10.1056/NEJMsr070105; PMID: 17442911
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9:631 - 43; http://dx.doi.org/10.1038/nrc2713; PMID: 19701242
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010; 11:1135 - 41; http://dx.doi.org/10.1016/S1470-2045(10)70257-6; PMID: 21087898
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687 - 717; http://dx.doi.org/10.1016/S0140-6736(05)66544-0; PMID: 15894097
   PubMed Web of Science ®Google Scholar
• Higgins MJ, Rae JM, Flockhart DA, Hayes DF, Stearns V. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?. J Natl Compr Canc Netw 2009; 7:203 - 13; PMID: 19200418
   PubMed Web of Science ®Google Scholar
• Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003; 144:1032 - 44; http://dx.doi.org/10.1210/en.2002-220620; PMID: 12586780
   PubMed Web of Science ®Google Scholar
• Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008; 29:217 - 33; http://dx.doi.org/10.1210/er.2006-0045; PMID: 18216219
   PubMed Web of Science ®Google Scholar
• Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008; 68:826 - 33; http://dx.doi.org/10.1158/0008-5472.CAN-07-2707; PMID: 18245484
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, et al. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004; 10:346S - 54S; http://dx.doi.org/10.1158/1078-0432.CCR-031206; PMID: 14734490
   PubMed Web of Science ®Google Scholar
• Dorssers LC, van Agthoven T, Dekker A, van Agthoven TL, Kok EM. Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: identification of bcar-1, a common integration site. Mol Endocrinol 1993; 7:870 - 8; http://dx.doi.org/10.1210/me.7.7.870; PMID: 8413311
   PubMed Web of Science ®Google Scholar
• Brinkman A, de Jong D, Tuinman S, Azaouagh N, van Agthoven T, Dorssers LC. The substrate domain of BCAR1 is essential for anti-estrogen-resistant proliferation of human breast cancer cells. Breast Cancer Res Treat 2010; 120:401 - 8; http://dx.doi.org/10.1007/s10549-009-0403-4; PMID: 19412734
   PubMed Web of Science ®Google Scholar
• Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006; 97:263 - 74; http://dx.doi.org/10.1007/s10549-005-9120-9; PMID: 16333527
   PubMed Web of Science ®Google Scholar
• Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003; 95:353 - 61; http://dx.doi.org/10.1093/jnci/95.5.353; PMID: 12618500
   PubMed Web of Science ®Google Scholar
• Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008; 456:663 - 6; http://dx.doi.org/10.1038/nature07483; PMID: 19005469
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, et al. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007; 7:59; http://dx.doi.org/10.1186/1471-2407-7-59; PMID: 17407600
   PubMed Web of Science ®Google Scholar
• Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005; 23:2469 - 76; http://dx.doi.org/10.1200/JCO.2005.01.172; PMID: 15753463
   PubMed Web of Science ®Google Scholar
• Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010; 120:2406 - 13; http://dx.doi.org/10.1172/JCI41680; PMID: 20530877
   PubMed Web of Science ®Google Scholar
• Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, et al. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. Clin Cancer Res 2011; 17:2024 - 34
   PubMed Web of Science ®Google Scholar
• Nehra R, Riggins RB, Shajahan AN, Zwart A, Crawford AC, Clarke R. BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. FASEB J 2010; 24:2040 - 55; http://dx.doi.org/10.1096/fj.09-138305; PMID: 20154269
   PubMed Web of Science ®Google Scholar
• Planas-Silva MD, Bruggeman RD, Grenko RT, Smith JS. Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer. Exp Mol Pathol 2007; 82:85 - 90; http://dx.doi.org/10.1016/j.yexmp.2006.09.001; PMID: 17046747
   PubMed Web of Science ®Google Scholar
• Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol 1998; 18:4499 - 508; PMID: 9671459
   PubMed Web of Science ®Google Scholar
• Stendahl M, Kronblad A, Ryden L, Emdin S, Bengtsson NO, Landberg G. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 2004; 90:1942 - 8; http://dx.doi.org/10.1038/sj.bjc.6601831; PMID: 15138475
   PubMed Web of Science ®Google Scholar
• Dhillon NK, Mudryj M. Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene 2002; 21:4626 - 34; http://dx.doi.org/10.1038/sj.onc.1205576; PMID: 12096339
   PubMed Web of Science ®Google Scholar
• Carroll JS, Lynch DK, Swarbrick A, Renoir JM, Sarcevic B, Daly RJ, et al. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. Cancer Res 2003; 63:4322 - 6; PMID: 12907598
   PubMed Web of Science ®Google Scholar
• Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci USA 2000; 97:9042 - 6; http://dx.doi.org/10.1073/pnas.160016897; PMID: 10908655
   PubMed Web of Science ®Google Scholar
• Roberts CG, Millar EK, O'Toole SA, McNeil CM, Lehrbach GM, Pinese M, et al. Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene 2011; 30:3186 - 97
   PubMed Web of Science ®Google Scholar
• Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J, et al. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 2009; 27:3423 - 9; http://dx.doi.org/10.1200/JCO.2008.17.2254; PMID: 19487384
   PubMed Web of Science ®Google Scholar
• Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009; 9:576 - 86; http://dx.doi.org/10.1038/nrc2683; PMID: 19629072
   PubMed Web of Science ®Google Scholar
• Nazarewicz RR, Zenebe WJ, Parihar A, Larson SK, Alidema E, Choi J, et al. Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. Cancer Res 2007; 67:1282 - 90; http://dx.doi.org/10.1158/0008-5472.CAN-06-3099; PMID: 17283165
   PubMed Web of Science ®Google Scholar
• Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 2000; 92:1926 - 34; http://dx.doi.org/10.1093/jnci/92.23.1926; PMID: 11106684
   PubMed Web of Science ®Google Scholar
• Seth P, Krop I, Porter D, Polyak K. Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression). Oncogene 2002; 21:836 - 43; http://dx.doi.org/10.1038/sj.onc.1205113; PMID: 11850811
   PubMed Web of Science ®Google Scholar
• Zhang Q, Gu J, Li L, Liu J, Luo B, Cheung HW, et al. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell 2009; 16:413 - 24; http://dx.doi.org/10.1016/j.ccr.2009.09.029; PMID: 19878873
   PubMed Web of Science ®Google Scholar
• Woodward TL, Mienaltowski AS, Modi RR, Bennett JM, Haslam SZ. Fibronectin and the alpha(5)beta(1) integrin are under developmental and ovarian steroid regulation in the normal mouse mammary gland. Endocrinology 2001; 142:3214 - 22; http://dx.doi.org/10.1210/en.142.7.3214; PMID: 11416044
   PubMed Web of Science ®Google Scholar
• Schedin P, Mitrenga T, McDaniel S, Kaeck M. Mammary ECM composition and function are altered by reproductive state. Mol Carcinog 2004; 41:207 - 20; http://dx.doi.org/10.1002/mc.20058; PMID: 15468292
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Hayashi S. Estrogen-related cancer microenvironment of breast carcinoma. Endocr J 2009; 56:1 - 7; http://dx.doi.org/10.1507/endocrj.K08E-099; PMID: 18497452
   PubMed Web of Science ®Google Scholar
• Giulianelli S, Cerliani JP, Lamb CA, Fabris VT, Bottino MC, Gorostiaga MA, et al. Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis. Int J Cancer 2008; 123:2518 - 31; http://dx.doi.org/10.1002/ijc.23802; PMID: 18767044
   PubMed Web of Science ®Google Scholar
• Shekhar MP, Santner S, Carolin KA, Tait L. Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. Am J Pathol 2007; 170:1546 - 60; http://dx.doi.org/10.2353/ajpath.2007.061004; PMID: 17456761
   PubMed Web of Science ®Google Scholar
• Witkiewicz AK, Casimiro MC, Dasgupta A, Mercier I, Wang C, Bonuccelli G, et al. Towards a new “stromal-based” classification system for human breast cancer prognosis and therapy. Cell Cycle 2009; 8:1654 - 8; http://dx.doi.org/10.4161/cc.8.11.8544; PMID: 19448435
   PubMed Web of Science ®Google Scholar
• Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, et al. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol 2009; 174:2035 - 43; http://dx.doi.org/10.2353/ajpath.2009.080924; PMID: 19411449
   PubMed Web of Science ®Google Scholar
• Koo JS, Park S, Kim SI, Lee S, Park BW. The impact of caveolin protein expression in tumor stroma on prognosis of breast cancer. Tumour Biol 2011; 32:787 - 99
   PubMed Web of Science ®Google Scholar
• Qian N, Ueno T, Kawaguchi-Sakita N, Kawashima M, Yoshida N, Mikami Y, et al. Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients. Cancer Sci 2011; 102:1590 - 6
   PubMed Web of Science ®Google Scholar
• Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 2009; 174:2023 - 34; http://dx.doi.org/10.2353/ajpath.2009.080873; PMID: 19411448
   PubMed Web of Science ®Google Scholar
• Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, Milliman JN, Chiavarina B, et al. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: Implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 2010; 9:2423 - 33; http://dx.doi.org/10.4161/cc.9.12.12048; PMID: 20562526
   PubMed Web of Science ®Google Scholar
• Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 2010; 9:3256 - 76; http://dx.doi.org/10.4161/cc.9.16.12553; PMID: 20814239
   PubMed Web of Science ®Google Scholar
• Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal microenvironment. Cell Cycle 2010; 9:3515 - 33; http://dx.doi.org/10.4161/cc.9.17.12928; PMID: 20855962
   PubMed Web of Science ®Google Scholar
• Pavlides S, Tsirigos A, Migneco G, Whitaker-Menezes D, Chiavarina B, Flomenberg N, et al. The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle 2010; 9:3485 - 505; http://dx.doi.org/10.4161/cc.9.17.12721; PMID: 20861672
   PubMed Web of Science ®Google Scholar
• Rabinowitz JD, White E. Autophagy and metabolism. Science 2010; 330:1344 - 8; http://dx.doi.org/10.1126/science.1193497; PMID: 21127245
   PubMed Web of Science ®Google Scholar
• Finn PF, Dice JF. Ketone bodies stimulate chaperone-mediated autophagy. J Biol Chem 2005; 280:25864 - 70; http://dx.doi.org/10.1074/jbc.M502456200; PMID: 15883160
   PubMed Web of Science ®Google Scholar
• Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, Witkiewicz AK, et al. Evidence for a stromal-epithelial “lactate shuttle” in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 2011; 10:1772 - 83; http://dx.doi.org/10.4161/cc.10.11.15659; PMID: 21558814
   PubMed Web of Science ®Google Scholar
• Hawley SA, Ross FA, Chevtzoff C, Green KA, Evans A, Fogarty S, et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 2010; 11:554 - 65; http://dx.doi.org/10.1016/j.cmet.2010.04.001; PMID: 20519126
   PubMed Web of Science ®Google Scholar
• El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000; 275:223 - 8; http://dx.doi.org/10.1074/jbc.275.1.223; PMID: 10617608
   PubMed Web of Science ®Google Scholar
• Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9:563 - 75; http://dx.doi.org/10.1038/nrc2676; PMID: 19629071
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004; 6:91 - 9; http://dx.doi.org/10.1016/j.ccr.2004.06.007; PMID: 15261145
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 2004; 101:3329 - 35; http://dx.doi.org/10.1073/pnas.0308061100; PMID: 14985505
   PubMed Web of Science ®Google Scholar
• Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66:10269 - 73; http://dx.doi.org/10.1158/0008-5472.CAN-06-1500; PMID: 17062558
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67:10804 - 12; http://dx.doi.org/10.1158/0008-5472.CAN-07-2310; PMID: 18006825
   PubMed Web of Science ®Google Scholar
• Mitchell RA, Chang BF, Huang CH, DeMaster EG. Inhibition of mitochondrial energy-linked functions by arsenate. Evidence for a nonhydrolytic mode of inhibitor action. Biochemistry 1971; 10:2049 - 54; http://dx.doi.org/10.1021/bi00787a013; PMID: 4327397
   PubMed Web of Science ®Google Scholar
• Miller WH Jr., Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62:3893 - 903; PMID: 12124315
   PubMed Web of Science ®Google Scholar
• Flora SJ. Arsenic-induced oxidative stress and its reversibility. Free Radic Biol Med 2011; 51:257 - 81
   PubMed Web of Science ®Google Scholar
• Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126:107 - 20; http://dx.doi.org/10.1016/j.cell.2006.05.036; PMID: 16839880
   PubMed Web of Science ®Google Scholar
• Bensaad K, Cheung EC, Vousden KH. Modulation of intracellular ROS levels by TIGAR controls autophagy. EMBO J 2009; 28:3015 - 26; http://dx.doi.org/10.1038/emboj.2009.242; PMID: 19713938
   PubMed Web of Science ®Google Scholar
• Howell A. Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr Relat Cancer 2006; 13:689 - 706; http://dx.doi.org/10.1677/erc.1.00846; PMID: 16954425
   PubMed Web of Science ®Google Scholar
• Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004; 22:1605 - 13; http://dx.doi.org/10.1200/JCO.2004.02.112; PMID: 15117982
   PubMed Web of Science ®Google Scholar
• Chen SJ, Zhou GB, Zhang XW, Mao JH, de The H, Chen Z. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 2011; 117:6425 - 37; http://dx.doi.org/10.1182/blood-2010-11-283598; PMID: 21422471
   PubMed Web of Science ®Google Scholar
• Pontiggia O, Rodriguez V, Fabris V, Raffo D, Bumaschny V, Fiszman G, et al. Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions. Breast Cancer Res Treat 2009; 116:247 - 55; http://dx.doi.org/10.1007/s10549-008-0113-3; PMID: 18622696
   PubMed Web of Science ®Google Scholar
• Samudio I, Fiegl M, McQueen T, Clise-Dwyer K, Andreeff M. The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res 2008; 68:5198 - 205; http://dx.doi.org/10.1158/0008-5472.CAN-08-0555; PMID: 18593920
   PubMed Web of Science ®Google Scholar
• Müerköster S, Wegehenkel K, Arlt A, Witt M, Sipos B, Kruse ML, et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 2004; 64:1331 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-03-1860; PMID: 14973050
   PubMed Web of Science ®Google Scholar
• Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE 2009; 4:e7965; http://dx.doi.org/10.1371/journal.pone.0007965; PMID: 19956757
   PubMed Web of Science ®Google Scholar
• Johnson JA, Pollak M. Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes. Diabetologia 2010; 53:2086 - 8; http://dx.doi.org/10.1007/s00125-010-1855-0; PMID: 20645073
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33:1674 - 85; http://dx.doi.org/10.2337/dc10-0666; PMID: 20587728
   PubMed Web of Science ®Google Scholar
• Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010; 33:1304 - 8; http://dx.doi.org/10.2337/dc09-1791; PMID: 20299480
   PubMed Web of Science ®Google Scholar
• Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32:1620 - 5; http://dx.doi.org/10.2337/dc08-2175; PMID: 19564453
   PubMed Web of Science ®Google Scholar
• Bosco JL, Antonsen S, Sorensen HT, Pedersen L, Lash TL. Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 2011; 20:101 - 11; http://dx.doi.org/10.1158/1055-9965.EPI-10-0817; PMID: 21119073
   PubMed Web of Science ®Google Scholar
• Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27:3297 - 302; http://dx.doi.org/10.1200/JCO.2009.19.6410; PMID: 19487376
   PubMed Web of Science ®Google Scholar
• Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 3:1077 - 83
   PubMed Web of Science ®Google Scholar
• Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) 3:1060 - 5
   PubMed Web of Science ®Google Scholar
• Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147:386 - 99; PMID: 17638715
   PubMed Web of Science ®Google Scholar
• Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327:951 - 3; http://dx.doi.org/10.1136/bmj.327.7421.951; PMID: 14576245
   PubMed Web of Science ®Google Scholar
• Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101:5328 - 35; http://dx.doi.org/10.1073/pnas.0400053101; PMID: 15044693
   PubMed Web of Science ®Google Scholar
• Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009; 27:504 - 10; http://dx.doi.org/10.1200/JCO.2008.18.6130; PMID: 19075265
   PubMed Web of Science ®Google Scholar
• Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, et al. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol 2009; 27:3430 - 6; http://dx.doi.org/10.1200/JCO.2008.18.4085; PMID: 19470942
   PubMed Web of Science ®Google Scholar
• Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009; 15:68 - 74; http://dx.doi.org/10.1038/nm.1908; PMID: 19122658
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817 - 26; http://dx.doi.org/10.1056/NEJMoa041588; PMID: 15591335
   PubMed Web of Science ®Google Scholar
• Sotgia F, Del Galdo F, Casimiro MC, Bonuccelli G, Mercier I, Whitaker-Menezes D, et al. Caveolin-1−/− null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. Am J Pathol 2009; 174:746 - 61; http://dx.doi.org/10.2353/ajpath.2009.080658; PMID: 19234134
   PubMed Web of Science ®Google Scholar
• Sotgia F, Casimiro MC, Bonuccelli G, Liu M, Whitaker-Menezes D, Er O, et al. Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation. Am J Pathol 2009; 174:613 - 29; http://dx.doi.org/10.2353/ajpath.2009.080653; PMID: 19164602
   PubMed Web of Science ®Google Scholar
• Chiavarina B, Whitaker-Menezes D, Migneco G, Martinez-Outschoorn UE, Pavlides S, Howell A, et al. HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis. Cell Cycle 2010; 9:3534 - 51; http://dx.doi.org/10.4161/cc.9.17.12908; PMID: 20864819
   PubMed Web of Science ®Google Scholar